Wall Street Zen Downgrades Altimmune to 'Sell' Rating

Analysts cite concerns over the company's financial performance and outlook

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Wall Street Zen has downgraded shares of biopharmaceutical company Altimmune (NASDAQ:ALT) from a 'hold' rating to a 'sell' rating in a research note issued to investors. Several other equity analysts have also recently weighed in on the stock, with some lowering their price targets and ratings.

Why it matters

This downgrade from Wall Street Zen and other analysts signals growing concerns about Altimmune's financial performance and future prospects, which could impact investor confidence and the company's ability to raise capital and fund its pipeline of vaccine and immunotherapy candidates.

The details

Wall Street Zen cited Altimmune's recent quarterly earnings results, in which the company reported a wider-than-expected loss. Other analysts have also lowered their price targets and ratings on Altimmune's stock, with concerns around the company's financial outlook and the progress of its drug development programs.

  • Altimmune reported its latest quarterly earnings results on March 5, 2026.
  • Wall Street Zen issued its downgrade on Altimmune on March 8, 2026.

The players

Altimmune

A clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, focused on developing vaccines and immunotherapeutics.

Wall Street Zen

An equity research firm that has downgraded Altimmune's stock from a 'hold' rating to a 'sell' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

This downgrade highlights the challenges Altimmune faces in advancing its pipeline and maintaining investor confidence, underscoring the competitive and volatile nature of the biopharmaceutical industry.